SYNTHESIS OF UP TO TEN SAMPLE COMPOUNDS PER YEAR (CONTINUITY FOR 66C)

每年合成多达十种样品化合物（66C 连续性）

• 批准号: 10503494
• 负责人: JAMES TALTON
• 金额: $ 61.87万
• 依托单位: ALCHEM LABORATORIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2022-09-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10503494
• 关键词: Contractor; Developmental Therapeutics Program; Drug Utilization; Human; Indoles; Pharmaceutical Preparations; Sampling; Therapeutic Agents; cancer therapy; clinical development; drug synthesis

The Developmental Therapeutics Program/DCTD utilizes the Drug Acquisition Initiative (DAI) to independently acquire gram quantities of all known therapeutic agents that are under human clinical development for the treatment of cancer. As part of the DAI the Drug Synthesis and Chemistry Branch periodically engages its contractors to synthesize gram quantities of select compounds. The Synthesis Target 1 Project is directed at the synthesis of a minimum of 5 grams of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, designated as CB-5339 and NSC831868.

发育治疗计划/DCTD利用药物获取计划（DAI）独立地获取了所有已知的已知治疗剂的革兰氏量，这些治疗剂属于人类临床开发以治疗癌症。 作为DAI的一部分，药物合成和化学分支定期聘请其承包商合成革兰氏量的精选化合物。 合成目标1项目的至少为5克1-（4-（4-（苯甲酰氨基））-5,6,7,8-四氢吡啶[2,3-D]吡啶二胺-2-基）-2-甲基-1H-Indole-1-4-羧酰胺，指定为CB-53339和NSC8398318。